



The Right Questions for the Right Answers

# Pathophysiology

THIRD EDITION

- ▶ 500 USMLE-type questions, answers, and explanations
- ▶ Rationales for correct and incorrect answers
- ▶ High-yield facts reinforce key concepts
- ▶ Student-tested and reviewed

*Maurice A. Mufson*



# **Pathophysiology**

**PreTest™ Self-Assessment and Review**  
**Third Edition**

**Maurice A. Mufson, M.D., M.A.C.P.**

Professor of Medicine Emeritus  
Chairman Emeritus  
Department of Medicine  
Marshall University School of Medicine  
Huntington, West Virginia

**McGraw-Hill**  
**Medical Publishing Division**

New York Chicago San Francisco Lisbon London Madrid Mexico City  
Milan New Delhi San Juan Seoul Singapore Sydney Toronto

**Pathophysiology: PreTest™ Self-Assessment and Review, Third Edition**

Copyright © 2005 by The McGraw-Hill Companies, Inc. All rights reserved. Printed in the United States of America. Except as permitted under the United States Copyright Act of 1976, no part of this publication may be reproduced or distributed in any form or by any means, or stored in a data base or retrieval system, without the prior written permission of the publisher.

Previous edition copyright © 2002, 1999 by The McGraw-Hill Companies, Inc.

PreTest is a trademark of The McGraw-Hill Companies, Inc.

2 3 4 5 6 7 8 9 0 DOC/DOC 0 9 8 7 6 5

ISBN 0-07-143492-5

*This book was set in Berkeley by North Market Street Graphics.*

*The editor was Catherine A. Johnson.*

*The production supervisor was Phil Galea.*

*Project management was provided by North Market Street Graphics.*

*The cover designer was Li Chen Chang / Pinpoint.*

*RR Donnelley was printer and binder.*

*This book is printed on acid-free paper.*

Cataloging-in-Publication data is on file for this title at the Library of Congress.



# **Pathophysiology**

PreTest™ Self-Assessment and Review

## **Notice**

Medicine is an ever-changing science. As new research and clinical experience broaden our knowledge, changes in treatment and drug therapy are required. The authors and the publisher of this work have checked with sources believed to be reliable in their efforts to provide information that is complete and generally in accord with the standards accepted at the time of publication. However, in view of the possibility of human error or changes in medical sciences, neither the authors nor the publisher nor any other party who has been involved in the preparation or publication of this work warrants that the information contained herein is in every respect accurate or complete, and they disclaim all responsibility for any errors or omissions or for the results obtained from use of the information contained in this work. Readers are encouraged to confirm the information contained herein with other sources. For example and in particular, readers are advised to check the product information sheet included in the package of each drug they plan to administer to be certain that the information contained in this work is accurate and that changes have not been made in the recommended dose or in the contraindications for administration. This recommendation is of particular importance in connection with new or infrequently used drugs.

# Contributors

---

**Henry K. Driscoll, M.D.**

Professor of Medicine  
Department of Medicine  
Marshall University School of Medicine  
Huntington, West Virginia

**Shirley M. Neitch, M.D.**

Professor of Medicine  
Section Chief of Geriatrics  
Department of Medicine  
Marshall University School of Medicine  
Huntington, West Virginia

**Paulette Wehner, M.D.**

Associate Professor of Medicine  
Director of Cardiology Fellowship  
Department of Cardiovascular Services  
Marshall University School of Medicine  
Huntington, West Virginia

**Jason Yap, M.D.**

Assistant Professor of Medicine  
Section Chief of Nephrology  
Department of Medicine  
Wright State University School of Medicine  
Dayton, Ohio

# Student Reviewers

---

**Franklin L. Chen**

Mount Sinai School of Medicine  
New York, New York  
Class of 2003

**Sarah Harper**

University of Pittsburgh School of Medicine  
Pittsburgh, Pennsylvania  
Class of 2005

**Michael Wolf**

UMDNJ—Robert Wood Johnson Medical School  
New Brunswick, New Jersey  
Class of 2004

# Introduction

---

In this Third Edition of *Pathophysiology PreTest™ Self-Assessment and Review*, many questions are new and more of them begin with a brief clinical vignette to frame the question and place the teaching point in a clinical context. The chapter on “High-Yield Facts” has been revised and expanded and represents a synopsis of significant points in the format of condensed summaries. These “High-Yield Facts” highlight key points in pathophysiology for rapid review. They provide a “memory jog” when reviewing the questions, and it is important to read the source reference citations accompanying them.

Testing your knowledge by answering the pathophysiology questions in this book serves as a competition in which you compete against yourself for the satisfaction of doing well. It’s a great feeling when you know the answers to difficult medical questions. It reflects well on your ability to learn the material in medical school, and it’s a signal that you’re prepared for the certifying examinations. This competition also can increase your knowledge base, as any competition sharpens your skills. That is an important part of testing ourselves. When we don’t know an answer, it’s an opportunity to look it up in a “big book” of internal medicine and improve our understanding of the topic. Each answer includes a reference to that answer, as a starting point for reading more about the topic. Although knowing the answer to any individual question provides some measure of satisfaction, it does not, and should not, represent a stopping point. Importantly, it should encourage you to read further so that you can easily answer questions from any point of view on that topic.

Consider using this book in the following manner:

- Read the question and then record your answer before you read the correct answer.
- Look at the correct answer and the explanation.
- Read the source reference citation.

The process of studying remains paramount, not necessarily whether you know the correct answer to one question or many questions. Don’t fail to consult the source reference citation listed for each question, especially the questions for which you do not readily know the answer. In this manner, you will increase the depth and breadth of your knowledge, which after all is the goal of testing yourself on these questions.



# Acknowledgments

---

Mentors open doors for us in a way that only mentors can do. They promote our career and help us to see its direction. Their interest and understanding make the difference in the paths we take. Several mentors aided me throughout differing times of my career and I want to acknowledge them: Harold Heine, Ph.D., at Bucknell University, my first research mentor; the late Pinckney Jones Harman, Ph.D., at New York University School of Medicine; H. Sherwood Lawrence, M.D., also of New York University School of Medicine, who guided me into a career in infectious disease; Robert M. Chanock, M.D., at the National Institutes of Allergy and Infectious Diseases, who nurtured my research endeavors in virus diseases; Morton D. Bogdonoff, M.D., at the University of Illinois College of Medicine, who encouraged my becoming a Chair of a Department of Medicine; Erling Norrby, M.D., Ph.D., of the Karolinska Institute, Stockholm, Sweden, who opened his laboratory to me for my sabbatical and inspired me; and my wife, Deedee, who guides, encourages, nurtures, and inspires me in all my endeavors, and without whom my career would not have been the joy that it is.

Maurice A. Mufson, M.D., M.A.C.P.  
Huntington, West Virginia



# **Pathophysiology**

PreTest™ Self-Assessment and Review

# Contents

|                                  |             |
|----------------------------------|-------------|
| <i>Introduction</i> . . . . .    | <b>xi</b>   |
| <i>Acknowledgments</i> . . . . . | <b>xiii</b> |

## **High-Yield Facts**

|                                                      |          |
|------------------------------------------------------|----------|
| <i>High-Yield Facts in Pathophysiology</i> . . . . . | <b>I</b> |
|------------------------------------------------------|----------|

## **Immune System**

|                                                        |           |
|--------------------------------------------------------|-----------|
| <i>Questions</i> . . . . .                             | <b>9</b>  |
| <i>Answers, Explanations, and References</i> . . . . . | <b>20</b> |

## **Genetic Disease**

|                                                        |           |
|--------------------------------------------------------|-----------|
| <i>Questions</i> . . . . .                             | <b>29</b> |
| <i>Answers, Explanations, and References</i> . . . . . | <b>40</b> |

## **Neoplasia and Blood Disorders**

|                                                        |           |
|--------------------------------------------------------|-----------|
| <i>Questions</i> . . . . .                             | <b>51</b> |
| <i>Answers, Explanations, and References</i> . . . . . | <b>62</b> |

## **Infectious Disease**

|                                                        |           |
|--------------------------------------------------------|-----------|
| <i>Questions</i> . . . . .                             | <b>71</b> |
| <i>Answers, Explanations, and References</i> . . . . . | <b>83</b> |

## **Cardiovascular System**

|                                                        |            |
|--------------------------------------------------------|------------|
| <i>Questions</i> . . . . .                             | <b>93</b>  |
| <i>Answers, Explanations, and References</i> . . . . . | <b>106</b> |

## **Pulmonary System**

|                                                        |            |
|--------------------------------------------------------|------------|
| <i>Questions</i> . . . . .                             | <b>123</b> |
| <i>Answers, Explanations, and References</i> . . . . . | <b>129</b> |

## **Renal System/Nephrology**

|                                                 |     |
|-------------------------------------------------|-----|
| Questions . . . . .                             | 135 |
| Answers, Explanations, and References . . . . . | 146 |

## **Gastroenterology**

|                                                 |     |
|-------------------------------------------------|-----|
| Questions . . . . .                             | 157 |
| Answers, Explanations, and References . . . . . | 169 |

## **Liver Disease**

|                                                 |     |
|-------------------------------------------------|-----|
| Questions . . . . .                             | 177 |
| Answers, Explanations, and References . . . . . | 188 |

## **Thyroid and Pituitary Disorders**

|                                                 |     |
|-------------------------------------------------|-----|
| Questions . . . . .                             | 197 |
| Answers, Explanations, and References . . . . . | 208 |

## **Reproductive System**

|                                                 |     |
|-------------------------------------------------|-----|
| Questions . . . . .                             | 217 |
| Answers, Explanations, and References . . . . . | 228 |

## **Nervous System**

|                                                 |     |
|-------------------------------------------------|-----|
| Questions . . . . .                             | 237 |
| Answers, Explanations, and References . . . . . | 251 |

|                        |     |
|------------------------|-----|
| Bibliography . . . . . | 261 |
|------------------------|-----|

|                 |     |
|-----------------|-----|
| Index . . . . . | 263 |
|-----------------|-----|

# High-Yield Facts

1. Many diseases have an immunologic basis. Example: Graft-versus-host disease (GVHD) can develop in an immunosuppressed individual who receives immunocompetent donor cells. The donor cells respond to histocompatibility antigens present on the recipient's cells that are NOT found on the donor cells. Bone marrow contains immunocompetent T cells. (Levinson, 7/e, p 798. Braunwald, 15/e, pp 741–742.)
2. The normal fetus and newborn produce only the IgM class of immunoglobulins in response to an antigen; any IgG that is present likely crossed the placenta as it is the only immunoglobulin that does so. (McPhee, 4/e, p 392.)
3. Persons with the autosomal dominant gene of type I osteogenesis imperfecta characteristically have blue scleras. (McPhee, 4/e, p 7. Braunwald, 15/e, pp 388–389.)
4. The most common cause of trisomy 21 is maternal nondisjunction. (McPhee, 4/e, pp 23–28.)
5. The following chart compares bacterial meningitis and viral meningitis. (McPhee, 4/e, pp 71–74.)

|                        | <b>Bacterial Meningitis</b>                                                                        | <b>Viral Meningitis</b>                                                                            |
|------------------------|----------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------|
| Disease state          | Acute: significant mortality without antibiotic therapy                                            | Acute: usually self-limited                                                                        |
| Symptoms               | Fever<br>Meningismus<br>Mental status changes                                                      | Fever<br>Meningismus<br>Mental status changes                                                      |
| Physical exam findings | Photophobia<br>Nausea<br>Vomiting<br>Fever<br>Kernig's sign—positive<br>Brudzinski's sign—positive | Photophobia<br>Nausea<br>Vomiting<br>Fever<br>Kernig's sign—positive<br>Brudzinski's sign—positive |
| Etiology               | Neonates<br><i>Escherichia coli</i><br>Group B streptococcus<br><i>Listeria monocytogenes</i>      | Coxsackie A and B viruses<br>Poliovirus<br>Mumps virus<br>Epstein-Barr virus                       |

(Continued)

|                                | Bacterial Meningitis                                                                                                                                                                                                        | Viral Meningitis                                                                                                |
|--------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------|
|                                | Children<br><i>Neisseria meningitidis</i><br><i>Streptococcus pneumoniae</i><br><i>Haemophilus influenzae</i> ,<br>nonimmunized                                                                                             | Adenovirus<br>Cytomegalovirus                                                                                   |
|                                | Adults (>18 years old)<br><i>N. meningitidis</i> ,<br>especially among<br>freshman and sophomore<br>college students who<br>reside in the dorms<br><i>S. pneumoniae</i><br><i>L. monocytogenes</i><br>Gram-negative bacilli | Enteroviruses<br>Arboviruses<br>HIV<br><i>Herpesvirus Simplex</i><br>LCMV                                       |
| Cerebrospinal<br>fluid results | Decreased glucose<br>Increased protein<br>Increased neutrophils<br>Increased pressure                                                                                                                                       | Normal glucose<br>Slightly increased protein<br>Increased monocytes<br>Normal or slightly<br>increased pressure |
|                                | Gram stain shows bacteria                                                                                                                                                                                                   | Gram stain shows no<br>bacteria                                                                                 |
| Treatment                      | IV antibiotics<br>Supportive therapy                                                                                                                                                                                        | Supportive therapy                                                                                              |
| Complications                  | Cerebral edema<br>Deafness<br>Death                                                                                                                                                                                         | Deafness<br>Weakness                                                                                            |

6. Carcinomas undergo phenotypic transition from **normal** → **hyperplasia** → **carcinoma in situ** → **invasive carcinoma** → **metastasis**. Carcinomas occur as a result of a constellation of physiologic and genetic changes (e.g., APC, hMLH1, and hMSH2—colon carcinoma/BRCA1 and BRCA2—breast carcinoma). (McPhee, 4/e, pp 96–101.)
7. Colon carcinoma begins when cell cycle regulation loses control over growth, and a collection of rapidly multiplying cells (hyperplasia) form an adenoma. The adenoma can continue to develop into carcinoma in situ. The first evidence of disease may be occult rectal bleeding indicating the appearance of new friable vessels supplying the tumor. Next,

the cancer cells invade the basement membrane of the colon (invasive carcinoma), gaining access to the body's transport systems (lymphatic and hematogenous). Metastasis to lymph nodes and distant body regions can occur. (McPhee, 4/e, pp 99–100.)

8. Many malignancies have characteristic indirect systemic effects via multiple mechanisms. Carcinoid syndromes produce serotonin or prostaglandins that can cause flushing, restrictive lung symptoms, ascites, and hypotension. Excess adrenocorticotrophic hormone (ACTH) production in small-cell bronchogenic carcinoma results in a Cushing-like syndrome, and excess antidiuretic hormone (ADH) production in these malignancies results in a syndrome of inappropriate antidiuretic hormone secretion (SIADH). Malignancies (e.g., squamous cell carcinoma) can produce peptides related to PTH, causing hypercalcemia. (McPhee, 4/e, pp 101–103. Braunwald, 15/e, p 2091.)
9. Pernicious anemia occurs when antibodies to intrinsic factor and parietal cells attack the gastric mucosa, causing gastric atrophy. The disruption of the normal function of the gastric mucosa affects vitamin B<sub>12</sub> absorption on two levels: stomach acid deficiency (achlorhydria) prevents the release of vitamin B<sub>12</sub> from food digestion, and intrinsic factor is necessary for vitamin B<sub>12</sub> absorption in the terminal ileum. The chronic loss of vitamin B<sub>12</sub> results in abnormal RBC maturation without changes in hemoglobin synthesis leading to macrocytic anemia. The Schilling test is abnormal and confirms the diagnosis. Patients with pernicious anemia require treatment with cobalamin, which reverses the anemia and the neurologic abnormalities. Folate treatment alone fails to reverse neurologic abnormalities of cobalamin deficiency. (McPhee, 4/e, pp 128–132; Braunwald, 15/e, pp 677–680.)
10. Pathophysiology of hearing loss (McPhee, 4/e, pp 166–167.)

| Type of Hearing Loss | Etiology                                                                                              | Testing                                                                         |
|----------------------|-------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------|
| Conductive deafness  | Disruption of conduction and amplification of sound from the external auditory canal to the inner ear | Negative Rinne test<br>Weber test: heard best in the affected ear<br>Audiometry |

(Continued)

| Type of Hearing Loss | Etiology                                             | Testing                                                                           |
|----------------------|------------------------------------------------------|-----------------------------------------------------------------------------------|
| Sensorineural        | Impaired function of inner ear or cranial nerve VIII | Positive Rinne test<br>Weber test: heard best in the unaffected ear<br>Audiometry |
| Central deafness     | Damaged CNS auditory pathways                        | Audiometry                                                                        |

11. Myasthenia gravis is an autoimmune disease characterized by antibodies to acetylcholine receptors, causing a deficiency in the number of acetylcholine receptors on the postsynaptic (muscle) terminal, resulting in reduced efficiency of neuromuscular activity. The disease commonly presents in small muscle groups, accompanied by intermittent fatigue and weakness relieved by rest. (*McPhee, 4/e, pp 174–175.*)
12. Psoriasis is an inflammatory parakeratotic accumulation of skin cells that features erythematous, demarcated lesions with scaly patches commonly found on scalp, extensor surfaces of extremities, and fingernails. The lesions appear pink/silver described as “salmon-like.” (*McPhee, 4/e, pp 193–196.*)
13. Asthma is an obstructive pulmonary disease characterized by airway narrowing as a result of smooth muscle spasms, inflammation, edema, and thick mucus production. The lung function tests (LFTs) show an obstructive picture with a decreased  $FEV_1/FVC$  ( $FEV_1\%$ ). The pathophysiologic response is mediated by local cellular injury, lymphocyte activation (antigen exposure, B cell activation, and cytokine activity), IgE-mediated mast cell (producing histamine, leukotrienes, and platelet-activating factor), and eosinophil activation. (*McPhee, 4/e, pp 236–240.*)
14. Pulmonary function tests: obstructive lung disease vs. restrictive lung disease. (*McPhee, 4/e, pp 240–246.*)



| Pulmonary Function Test                       | Obstructive Lung Disease<br>(e.g., Chronic Obstructive Pulmonary Disease) | Restrictive Lung Disease<br>(e.g., Pulmonary Fibrosis) |
|-----------------------------------------------|---------------------------------------------------------------------------|--------------------------------------------------------|
| FVC                                           | ↓                                                                         | ↓                                                      |
| FEV <sub>1</sub>                              | ↓                                                                         | ↓                                                      |
| FEV <sub>1</sub> %<br>(FEV <sub>1</sub> /FVC) | ↓                                                                         | Normal/↑                                               |
| TLC                                           | ↑                                                                         | ↓                                                      |
| RV                                            | ↑                                                                         | Normal/↓                                               |

15. Pulmonary embolism occurs when a venous thrombi (usually from a deep vein thrombosis) lodges in the pulmonary circulation. The pathophysiology includes hemodynamic changes, increased alveolar dead space with increased ventilation/perfusion ratios, and decreased oxygen perfusion to body tissues. Common acute presentations include tachypnea, hemoptysis, tachycardia, fever, cough, and pleuritic pain. Pulmonary embolism occurs in persons postoperatively and in persons who must sit for long periods, such as airplane travelers. (*McPhee, 4/e, pp 251–257.*)
16. In normal individuals, as left ventricular end-diastolic pressure or preload increases, stroke volume will increase proportionately. In patients who suffer heart failure, increased left ventricular end-diastolic pressure is not met with increased stroke volume, because the contractility is depressed and is unable to function; thus, the patient ultimately experiences heart failure. Frank-Starling curves or ventricular function curves are diagrams that show the relationship between stroke volume or cardiac output and preload or left ventricular end-diastolic volume. (*Braunwald, 15/e, pp 1313–1318.*)
17. Stable angina is caused by a fixed partial atherosclerotic plaque in one or more of coronary arteries that involves a 75% blockage. When at rest, blood flow is able to provide adequate oxygenation to the heart muscle. On exertion, oxygen demand increases. The partial occlusion prevents adequate oxygenation to the heart, resulting in chest discomfort that is relieved by rest. Unstable angina is caused by thrombus formation on a fissuring atherosclerotic plaque, which transiently prevents adequate oxygenation to the heart. The resulting ischemia causes chest discomfort whether at rest or during exertion. (*McPhee, 4/e, pp 292–294.*)